Paris - Delayed Quote EUR
Genfit S.A. (GNFT.PA)
At close: October 18 at 5:35 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
28,565.00
28,565.00
20,195.00
80,069.00
765.00
--
Cost of Revenue
341.00
341.00
251.00
162.00
202.00
--
Gross Profit
28,224.00
28,224.00
19,944.00
79,907.00
563.00
--
Operating Expense
55,389.00
55,389.00
47,259.00
47,536.00
78,072.00
--
Operating Income
-27,165.00
-27,165.00
-27,315.00
32,371.00
-77,509.00
--
Net Non Operating Interest Income Expense
-1,419.00
-1,419.00
-3,676.00
30,944.00
-10,227.00
--
Other Income Expense
72.00
72.00
7,157.00
6,157.00
-13,913.00
--
Pretax Income
-28,514.00
-28,514.00
-23,836.00
69,474.00
-101,649.00
--
Tax Provision
380.00
380.00
-116.00
2,215.00
-428.00
--
Net Income Common Stockholders
-28,894.00
-28,894.00
-23,719.00
67,259.00
-101,221.00
--
Diluted NI Available to Com Stockholders
-28,894.00
-28,894.00
-23,719.00
67,259.00
-101,221.00
--
Basic EPS
-0.58
-0.58
-0.48
1.51
-2.60
--
Diluted EPS
-0.58
-0.58
-0.48
1.23
-2.60
--
Basic Average Shares
49,700.22
49,817.24
49,673.94
44,739.76
38,858.62
--
Diluted Average Shares
49,700.22
49,817.24
49,673.94
55,613.63
38,858.62
--
Total Operating Income as Reported
-26,580.00
-26,580.00
-27,289.00
31,816.00
-82,897.00
--
Total Expenses
55,730.00
55,730.00
47,510.00
47,698.00
78,274.00
--
Net Income from Continuing & Discontinued Operation
-28,894.00
-28,894.00
-23,719.00
67,259.00
-101,221.00
--
Normalized Income
-28,965.04
-28,965.04
-30,841.17
61,298.30
-87,366.43
--
Interest Income
1,709.00
1,709.00
137.00
274.00
1,442.00
--
Interest Expense
4,624.00
4,624.00
4,410.00
4,955.00
11,777.00
--
Net Interest Income
-1,419.00
-1,419.00
-3,676.00
30,944.00
-10,227.00
--
EBIT
-23,890.00
-23,890.00
-19,426.00
74,429.00
-89,872.00
--
EBITDA
-22,236.00
-22,236.00
-17,594.00
77,171.00
-86,313.00
--
Reconciled Cost of Revenue
341.00
341.00
251.00
162.00
202.00
--
Reconciled Depreciation
1,654.00
1,654.00
1,832.00
2,742.00
3,559.00
--
Net Income from Continuing Operation Net Minority Interest
-28,894.00
-28,894.00
-23,719.00
67,259.00
-101,221.00
--
Total Unusual Items Excluding Goodwill
72.00
72.00
7,157.00
6,157.00
-13,913.00
--
Total Unusual Items
72.00
72.00
7,157.00
6,157.00
-13,913.00
--
Normalized EBITDA
-22,308.00
-22,308.00
-24,751.00
71,014.00
-72,400.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
0.96
0.96
34.83
196.30
-58.43
--
12/31/2019 - 12/19/2006
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
OSE.PA OSE Immunotherapeutics SA
9.83
+9.47%
ADOC.PA Adocia SA
7.49
+21.00%
IPH.PA Innate Pharma S.A.
1.8700
-1.27%
ALVAL.PA Valbiotis SA
1.3020
-0.46%
ALCOX.PA Nicox S.A.
0.2680
+1.32%
NANO.PA Nanobiotix S.A.
4.4800
+1.40%
VLA.PA Valneva SE
2.6600
+4.31%
PHXM.PA PHAXIAM Therapeutics S.A.
1.7600
-2.11%
ALDVI.PA Advicenne S.A.
1.8960
-5.20%
POXEL.PA Poxel S.A.
0.3185
-2.90%